Ferring holding sa completed the acquisition of worldwide rights including certain fixed assets, for zomajet from antares pharma, inc. (nasdaqcm:atrs).

Ferring holding sa entered into a definitive asset purchase agreement to acquire worldwide rights including certain fixed assets, for zomajet from antares pharma, inc. (nasdaqcm:atrs) for $14.5 million on october 10, 2017. under the terms of deal, ferring will pay $2 million upfront, $2.8 million upon satisfaction of certain conditions, $4.8 million upon satisfaction of customary closing conditions and remaining $5 million at closing. the transaction is subject to certain customary closing conditions and expected to be completed by the end of 2018. antares intends to use consideration to invest in supporting the potential launch of it's next proprietary product, xyosted. as of march 1, 2018, ferring paid second installment of $2.75 million to antares pharma. as of may 30, 2018, ferring paid third installment of $4.75 million to antares pharma. in the second quarter ferring paid $4.75 million to antares pharma. as on august 6, 2019 antares pharma received $2.5 million in the second quarter from ferring pharmaceuticals and will receive final installment of $2.5 million in the second half of 2019. as of october 28, 2019 antares pharma received the final payment of $2.5 million from ferring pharmaceuticals. as on august 6, 2019 the transaction expected to close in the second half of 2019. dechert llp acted as acted as legal advisor to ferring holding sa. ferring holding sa completed the acquisition of worldwide rights including certain fixed assets, for zomajet from antares pharma, inc. (nasdaqcm:atrs) on october 28, 2019.
ATRS Ratings Summary
ATRS Quant Ranking